Lipocine Inc.
LPCN· Nasdaq
Released Mar 9, 2022, before the open
10-K filed Mar 9, 2022, 68 days after period end · 0001493152-22-006353
derived · Computed from the longer spans the company filed.
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019dderived from reported figures | Q4 2018 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Net Income | $12.62M | -$4.51M | -$3.29M | -$3.23M |
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR
| EPS Diluted |
|---|
| — |
| — |
| — |
| -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.